ReviewAACE endocrinology and diabetes

Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema.

Maxim John Levy Barnett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.